Nevro Corp (NYSE:NVRO) CFO Andrew H. Galligan sold 2,782 shares of Nevro stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $120.00, for a total value of $333,840.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Andrew H. Galligan also recently made the following trade(s):
- On Wednesday, January 8th, Andrew H. Galligan sold 17,718 shares of Nevro stock. The stock was sold at an average price of $120.11, for a total value of $2,128,108.98.
- On Monday, November 25th, Andrew H. Galligan sold 12,000 shares of Nevro stock. The stock was sold at an average price of $110.39, for a total value of $1,324,680.00.
- On Monday, November 11th, Andrew H. Galligan sold 18,522 shares of Nevro stock. The stock was sold at an average price of $103.70, for a total value of $1,920,731.40.
Shares of Nevro stock traded up $4.28 during trading on Thursday, reaching $122.55. 9,419 shares of the company’s stock were exchanged, compared to its average volume of 343,221. The company has a debt-to-equity ratio of 0.91, a quick ratio of 4.54 and a current ratio of 5.87. Nevro Corp has a 1-year low of $40.52 and a 1-year high of $120.74. The company has a market cap of $3.68 billion, a P/E ratio of -74.41 and a beta of 0.38. The firm’s 50-day moving average price is $114.37 and its 200 day moving average price is $89.62.
Nevro (NYSE:NVRO) last posted its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.27. Nevro had a negative return on equity of 46.35% and a negative net margin of 25.94%. The company had revenue of $100.16 million during the quarter, compared to analysts’ expectations of $92.27 million. During the same quarter in the previous year, the firm earned ($0.37) EPS. Nevro’s revenue was up 4.7% on a year-over-year basis. As a group, equities research analysts predict that Nevro Corp will post -3.65 EPS for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of NVRO. Invesco Ltd. increased its holdings in Nevro by 316.2% in the 2nd quarter. Invesco Ltd. now owns 1,970,969 shares of the medical equipment provider’s stock worth $127,778,000 after purchasing an additional 1,497,455 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Nevro by 91.5% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,078,635 shares of the medical equipment provider’s stock valued at $199,588,000 after buying an additional 1,470,807 shares during the last quarter. Perceptive Advisors LLC grew its position in shares of Nevro by 172.9% in the 2nd quarter. Perceptive Advisors LLC now owns 1,137,765 shares of the medical equipment provider’s stock valued at $73,761,000 after buying an additional 720,816 shares during the last quarter. Redmile Group LLC grew its position in shares of Nevro by 18,837.2% in the 3rd quarter. Redmile Group LLC now owns 643,864 shares of the medical equipment provider’s stock valued at $55,353,000 after buying an additional 640,464 shares during the last quarter. Finally, Nuveen Asset Management LLC bought a new stake in shares of Nevro in the 2nd quarter valued at about $26,818,000.
Several research firms have weighed in on NVRO. Morgan Stanley boosted their price target on Nevro from $100.00 to $125.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 17th. ValuEngine downgraded Nevro from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Wells Fargo & Co lifted their target price on Nevro from $86.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Canaccord Genuity lifted their target price on Nevro from $59.00 to $88.00 and gave the stock a “hold” rating in a research note on Thursday, November 7th. Finally, Oppenheimer restated a “market perform” rating on shares of Nevro in a research note on Monday, January 6th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and seven have given a buy rating to the company’s stock. Nevro currently has an average rating of “Hold” and an average target price of $94.00.
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Featured Article: Coverage Ratio
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.